Your search
Results 2 resources
-
Background: The clinical course of lipedema in women receiving hormonal treatment for concomitant estrogen-dependent gynecological disorders remains insufficiently characterized. This study aimed to describe gynecological and lipedema-related manifestations during routine follow-up in women receiving subcutaneous gestrinone implants for gynecological indications. Methods: This retrospective, descriptive case series included 50 women with stage II or III lipedema and concomitant estrogen-dependent gynecological disorders treated between May 2024 and May 2025 at a specialized multidisciplinary outpatient clinic in São Paulo, Brazil. Participants received two biodegradable subcutaneous gestrinone implants (35 mg and 50 mg; total dose: 85 mg) exclusively for gynecological indications. Clinical outcomes were extracted retrospectively from medical records and analyzed descriptively. Improvement proportions were calculated using the number of patients presenting each manifestation at baseline as the denominator. Outcomes were based on patient reports and qualitative clinical assessments without standardized instruments. Results: Among gynecological manifestations, improvement was documented in 43 of 50 patients with menstrual pain (86%), six of 13 with menorrhagia (46.2%), and two of 50 with premenstrual symptoms (4%). Among lipedema-related manifestations, improvement was documented in 35 of 39 patients with edema (89.7%) and 33 of 41 with spontaneous pain (80.5%). Qualitative improvement in skin appearance and clinically assessed tissue fibrosis was documented in 31 of 50 (62%) and 28 of 50 (56%) patients, respectively. Overall clinical status was reported as improved by 42 patients (84%), stable by six (12%), and worsened by two (4%). Conclusions: Improvements in pain and edema, alongside qualitative changes in skin appearance and clinically assessed tissue fibrosis, were documented during routine follow-up. Given the retrospective design, absence of a comparison group, and nonstandardized assessments, these observations cannot be attributed to gestrinone or interpreted as evidence of its efficacy for lipedema. Prospective controlled studies using standardized outcome measures are warranted.
-
PURPOSE: This study aimed to compare 12-week changes in body composition and anthropometric parameters between standard-dose and lower-dose tirzepatide escalation regimens in women with lipedema, with particular emphasis on changes in fat mass and skeletal muscle mass. PATIENTS AND METHODS: This retrospective observational study included 100 women with lipedema receiving tirzepatide during routine clinical care. Participants were classified into lower-dose (n = 50) and standard-dose (n = 50) groups according to their prescribed dosing regimens, which differed in cumulative drug exposure. Body composition, anthropometric measurements, and skinfold thickness were assessed at baseline and after 12 weeks. An exploratory composite responder criterion was defined as a ≥5% reduction in fat mass combined with a <5% reduction in skeletal muscle mass, as estimated by bioelectrical impedance analysis (BIA). Between-group comparisons were unadjusted. RESULTS: Both regimens were associated with reductions in body weight, fat mass, and body fat percentage (all within-group p < 0.001). No statistically significant between-group differences were detected in these changes. The lower-dose regimen was associated with a smaller reduction in BIA-estimated skeletal muscle mass than the standard-dose regimen (-0.7 vs. -2.0 kg; p < 0.001). The exploratory composite responder criterion was met by 68% (34/50) of participants in the lower-dose group and 22% (11/50) in the standard-dose group (OR = 7.53; 95% CI: 3.08-18.44; p < 0.001). No statistically significant between-group differences were detected in anthropometric measurements or skinfold thickness changes. CONCLUSION: Both tirzepatide dosing regimens were associated with reductions in body weight and adiposity in women with lipedema. The lower-dose regimen was associated with a smaller reduction in BIA-estimated skeletal muscle mass and a higher proportion of participants meeting the exploratory composite responder criterion. These findings require confirmation in prospective controlled studies, given the non-randomized design, differences in cumulative drug exposure, and potential residual confounding.
Explore
Topic
- Lipedema (2)
- Original studies and data (2)
Resource type
Publication year
-
Between 2000 and 2026
(2)
-
Between 2020 and 2026
(2)
- 2026 (2)
-
Between 2020 and 2026
(2)